Jump to content
Powered by BIOPRO BW
  • BIOPRO BW
  • Healthcare industry
  • Project pages
    • MDR & IVDR
    • Innovation & Startups

Healthcare industry Logo

Main navigation

  • Start page Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close Close
  • Databases

    Databases

    Close Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 04/12/2024

    Joint research in key technologies: NMI and KIT sign cooperation agreement

    The NMI Natural and Medical Sciences Institute and the Karlsruhe Institute of Technology (KIT) have signed a groundbreaking cooperation agreement. This partnership combines the expertise of both institutions in the fields of production and characterization of materials for biological systems and energy storage as well as the application of statistical methods in medicine.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/joint-research-key-technologies-nmi-and-kit-sign-cooperation-agreement
  • Press release - 15/11/2024

    Selenium proteins as a possible new target for cancer research

    An important enzyme helps the body produce selenium proteins – this discovery could open up new strategies for treating cancer in children. This has been published by scientists from the University of Würzburg, the University Sao Paolo, the German Cancer Research Center (DKFZ) and the Heidelberg Stem Cell Institute HI-STEM*.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/selenium-proteins-possible-new-target-cancer-research
  • Press release - 30/10/2024

    Diabetes switch in DNA: Non-coding region in the genome influences ONECUT1 gene

    They are underestimated genetic control elements: it is known that changes in the genome can trigger diabetes. But now researchers at the University Hospital Ulm and the INSERM Cochin Institute in Paris have shown that a previously under-researched region of the genome also plays a crucial role in the development of this disease.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/diabetes-switch-dna-non-coding-region-genome-influences-onecut1-gene
  • Press release - 01/10/2024

    Reporter Skin: In-vitro Skin Makes Cell Reaction to Test Substance Measurable in Real Time

    At the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, a three-dimensional skin model has now been set up for the first time that directly displays the skin's reaction to substances: The reporter skin. Thanks to the built-in reporter, the cellular response can be measured precisely and quickly – using a living model.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/reporter-skin-vitro-skin-makes-cell-reaction-test-substance-measurable-real-time
  • Press release - 25/09/2024

    How do rare genetic variants affect health? AI provides more accurate predictions

    Whether we are predisposed to particular diseases depends to a large extent on the countless variants in our genome. However in the case of genetic variants the influence on the presentation of certain pathological traits has been difficult to determine. Researchers have introduced an algorithm based on deep learning that can predict the effects of rare genetic variants.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/how-do-rare-genetic-variants-affect-health-ai-provides-more-accurate-predictions
  • Press release - 19/09/2024

    Quality standards for looking into the tumor genome

    Personalized medicine with individually tailored therapies is becoming more a reality in cancer. This requires a look into the genetic material of tumors, a molecular diagnostic tumor profile. A research group from the German Network for Personalized Medicine (DNPM) has recorded the quality standards according to which genome analyses are carried out in Germany. The data is a prerequisite for integrating gene sequencing into routine care.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/quality-standards-looking-tumor-genome
  • Press release - 17/09/2024

    Five new cross-border doctoral networks at Universität Heidelberg

    Five transnational and cross-institutional doctoral networks at Heidelberg University are being funded as part of the “Marie Skłodowska-Curie Actions”. They work together on current scientific topics with high innovation potential. Ruperto Carola coordinates an MSCA Doctoral Network on artificial intelligence in physics, two networks in medicine, life sciences and engineering.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/five-new-cross-border-doctoral-networks-universitat-heidelberg
  • Press release - 12/09/2024

    Power-to-vitamins: microbes produce folate from simple basic ingredients

    Biotechnology team at University of Tübingen obtains valuable byproduct in protein production. This could be a potential to the contribution of feeding a growing world population without livestock farming.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/power-vitamins-microbes-produce-folate-simple-basic-ingredients
  • Press release - 09/09/2024

    New Molecular Engineering Technique allows for complex Organoids

    A new molecular engineering technique can precisely influence the development of organoids. Microbeads made of specifically folded DNA are used to release growth factors or other signal molecules inside the tissue structures. This gives rise to considerably more complex organoids that imitate the respective tissues much better and have a more realistic cell mix than before.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-molecular-engineering-technique-allows-complex-organoids
  • Press release - 05/09/2024

    Cohesion at the cellular level: flexible yet stable

    Research teams from the Universities of Konstanz and Potsdam are analyzing how proteins work together to enable our cells to both stick and move. The marker protein paxillin is at the centre of their interest.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cohesion-cellular-level-flexible-yet-stable
  • Press release - 26/08/2024

    Synthetic Immunology: Approaching a Turning Point in the Treatment and Prevention of Disease

    Synthetic immunology is the topic of an article in the “Perspectives” section of the journal “Nature Nanotechnology”. Herein, Heidelberg researchers describe a so-called bottom-up approach that uses the toolbox of nanotechnology and synthetic biology to construct systems from molecular building blocks and specifically equip them with immune functions.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/synthetic-immunology-approaching-turning-point-treatment-and-prevention-disease
  • Press release - 22/08/2024

    Validated targets for personalized cancer immunotherapy

    Knowledge of the target structures for the immune cells is a basic prerequisite for the development of personalized cancer immunotherapies. Scientists from the German Cancer Research Center and the NCT Heidelberg are publishing a sensitive method based on mass spectroscopy to identify such tumor-specific "neoepitopes". The analytical method is designed to detect these low abundance protein fragments and requires minimal amounts of…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/validated-targets-personalized-cancer-immunotherapy
  • Press release - 21/08/2024

    A molecular control hub maintains order

    How are proteins in our cells modified while they are still being synthesized? An international team of researchers from the University of Konstanz, Caltech, and ETH Zurich has deciphered the molecular mechanism of this vital process.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/molecular-control-hub-maintains-order
  • Press release - 14/08/2024

    New vaccine against cervical cancer combines prophylactic and therapeutic activities

    Scientists at the German Cancer Research Center (DKFZ) have developed a completely new vaccination concept. The vaccine is inexpensive and protects mice against almost all cancer-causing HPV types. In addition to preventing new infections, the vaccine also triggers cellular immune responses against HPV-infected cells and may therefore also have a therapeutic effect against existing infections.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-vaccine-against-cervical-cancer-combines-prophylactic-and-therapeutic-activities
  • Press release - 13/08/2024

    Peptide Boronic Acids: New Prospects for Immunology

    A cutting-edge chemical process is the first to make it possible to quickly and easily produce modified peptides with boronic acids. As part of this work, scientists managed to synthesize a large number of different biologically active peptide boronic acids and investigate their properties. They open up new possibilities in the young research field of synthetic immunology and could go on to be used primarily in immunotherapy.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/peptide-boronic-acids-new-prospects-immunology
  • Press release - 10/07/2024

    HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration

    HepaRegeniX GmbH, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, announced the closing of a Series C round led by Vesalius Biocapital IV with participation of existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and High-Tech Gründerfonds. The new funds of €15 million will be used to advance the clinical development of the clinical candidate HRX-215.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/heparegenix-raises-euro-15-million-series-c-round-advance-clinical-development-hrx-215-liver-regeneration
  • TWYCE GmbH - 10/07/2024 A micrograph shows how two T cells attack two tumour cells.

    Better immune response against prostate cancer thanks to new bispecific antibodies

    TWYCE, a Tübingen-based start-up spun off from the German Cancer Research Center in Heidelberg and the Faculty of Medicine at the University of Tübingen, is focused on developing a combinatorial therapy using two bispecific antibodies from bench to clinical practice. The founders aim to introduce an effective strategy for combating solid tumours, with initial proof of concept targeted at prostate cancer.

    https://www.gesundheitsindustrie-bw.de/en/article/news/better-immune-response-against-prostate-cancer-thanks-new-bispecific-antibodies
  • Press release - 09/07/2024

    Unique characteristics of previously unexplored protein discovered

    Freiburg-Prague research collaboration achieves scientific breakthrough in understanding cell division. The international research collaboration has uncovered a new mechanism of the crosstalk between microtubules and actin cytoskeleton during cell division and revealed unique characteristics of the previously unexplored protein FAM110A.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/unique-characteristics-previously-unexplored-protein-discovered
  • Press release - 05/07/2024

    Outstanding ideas – new imaging processes for cancer diagnostics and nanopropellers for ocular gene therapy

    The summer reception hosted by BioRegio STERN Management GmbH has once again provided a fitting backdrop for the Science2Start award ceremony. Last Thursday, at Tübingen observatory, was the 15th time that scientists and start-up founders were celebrated for outstanding ideas that a panel of experts judged to have special economic potential.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/outstanding-ideas-new-imaging-processes-cancer-diagnostics-and-nanopropellers-ocular-gene-therapy
  • Press release - 04/07/2024

    Antibody can improve immune cell therapy against leukemia

    Scientists from the German Cancer Research Center (DKFZ) and Heidelberg University Hospital (UKHD) have shown that the combination of therapeutic immune cells, known as CAR T cells, and a bispecific antibody could improve the treatment of leukaemia. In the culture dish and in mice, they tested CAR-T cells directed against the B-cell marker CD19 in combination with bispecific antibodies that bind to the B-cell-specific protein CD20.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/antibody-can-improve-immune-cell-therapy-against-leukemia
  • Press release - 17/06/2024

    DNA as building material for tiny machines and artificial cells

    Humboldt Research Award winner Prof. Hao Yan has been conducting research at the 2nd Institute of Physics at the University of Stuttgart since May. He is regarded as one of the world's leading experts in the field of DNA nanotechnology. "My work has many points of commonality with the topics that my colleagues in Stuttgart are focusing on," says Yan. "I have therefore been cooperating with Professor Laura Na Liu's working…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/dna-building-material-tiny-machines-and-artificial-cells
  • Press release - 13/06/2024

    Position of the cell nucleus affects epigenetics and therefore gene activity and cell function

    Depending on whether the cell nucleus of an epithelial cell is located on the outer or inner side of the tissue, the genome is more or less acetylated - genes can therefore be translated easier or harder. Scientists from the German Cancer Research Center (DKFZ) have demonstrated this for the first time in the development of the Drosophila wing.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/position-cell-nucleus-affects-epigenetics-and-therefore-gene-activity-and-cell-function
  • Press release - 31/05/2024

    Toolkit makes protein design faster and more accessible

    The Damietta Server broadens the accessibility to protein design research and its applications in various biotechnological and biomedical fields. Researchers at the Max Planck Institute for Biology Tübingen, the University of Tübingen, and the University Hospital Tübingen have developed a web-based toolkit to accelerate and simplify protein design without needing powerful computers or extensive protein design expertise on the user’s end.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/toolkit-makes-protein-design-faster-and-more-accessible
  • Press release - 22/05/2024

    Stretched beyond the limits of the cell: the molecular biomechanics of collagen

    Together with colleagues from Israel and USA, HITS researcher Frauke Gräter investigates the effects of physical force on the collagen protein in two different animal model systems. Their goal is to measure the effects of mechanoradicals on the integrity of the tissue and the well-being of the organism, with impact on health and aging.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/stretched-beyond-limits-cell-molecular-biomechanics-collagen
  • Press release - 07/05/2024

    Intermittent fasting protects against liver inflammation and liver cancer / Drug partially mimics fasting effects

    Fatty liver disease often leads to chronic liver inflammation and can even result in liver cancer. Scientists from the German Cancer Research Center (DKFZ) and the University of Tuebingen have now shown in mice that intermittent fasting can halt this development.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/intermittent-fasting-protects-against-liver-inflammation-and-liver-cancer-drug-partially-mimics-fasting-effects

Page 2 / 8

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 8
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • MDR & IVDR
    • Innovation & Startups
  • Portals
    • BIOPRO BW
    • Healthcare industry
  • To top

stay informed

Newsletter abonnieren

Social Media

  • Xing Xing
  • Twitter visit Twitter
  • LinkedIn visit LinkedIn
  • Rss visit RSS
  • Privacy statement
  • Accessability Declaration
  • Legal notice
  • Sitemap
  • Contact
© 2025
Website address: https://www.gesundheitsindustrie-bw.de/en/search